Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Inclusion Criteria: * Signed written informed consent form (ICF) * Age 18-75 years * Histologically/cytologically confirmed, unresectable locally advanced or metastatic pancreatic cancer. * Disease progression or intolerance after first-line treatment with the AG regimen (gemcitabine + albumin-bound paclitaxel). * ECOG Performance Status(PS) score of 0-1. * At least one measurable lesion according to RECIST v1.1 criteria. * Adequate organ and bone marrow function Exclusion Criteria: * Previous histologically/cytologically confirmed components including adenosquamous carcinoma, medullary carcinoma, signet ring cell carcinoma, undifferentiated carcinoma, etc. * Prior treatment with PD-1/PD-L1 inhibitors or other immunotherapies. * Unresolved \> Grade 1 toxicities related to prior anticancer therapy (except persistent Grade 2 alopecia, anemia, peripheral neuropathy, correctable electrolyte abnormalities, or well-controlled endocrine disorders with hormone replacement therapy). * History of hepatic encephalopathy, seizures, active/new/untreated CNS metastases, spinal compression, carcinomatous meningitis, or leptomeningeal metastases. * Clinically significant cardiovascular/cerebrovascular diseases * Known hypersensitivity to IL-2, sintilimab, or monoclonal antibody components